Silence Therapeutics plc — Director's Dealing 2020

May 12, 2020

National Storage Mechanism | Additional information

RNS Number : 6252M

Silence Therapeutics PLC

12 May 2020

PDMR Dealing

May 12, 2020

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces the following share trades by Dr. Rob Quinn, Chief Financial Officer of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Rob Quinn

2.

Reason for the notification

a)

Position / status

Chief Financial Officer

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

b)

LEI

213800SSURRJBX85SQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares in Silence Therapeutics plc

ISIN for Silence Therapeutics plc Ordinary Shares:

GB00B9GTXM62

b)

Nature of the transaction

Sale of Ordinary Shares in Silence Therapeutics plc

c)

Prices(a) and volume(s)

Price	Volume
£4.2921	15,942
£3.9804	73,112

d)

Aggregated information

- Aggregated volume

- Price

89,054 Ordinary Shares

£4.04

e)

Date of the transaction

7 and 11 May 2020

f)

Place of the transaction

London Stock Exchange, AIM

Enquiries:

Silence Therapeutics plc Iain Ross, Executive Chairman Dr Rob Quinn, Chief Financial Officer	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray [email protected]	Tel: +44 (0) 20 3709 5700
US IR Westwicke Partners Peter Vozzo [email protected]	Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHKKBBBFBKKFPD